Probing Yukawian Gravitational Potential by Numerical Simulations. II. Elliptical Galaxies

Since the Newtonian gravitation is largely used to model with success the structures of the universe, such as galaxies and clusters of galaxies, for example, a way to probe and constrain alternative theories, in the weak field limit, is to apply them to model the structures of the universe. We then modified the well known Gadget-2 code to probe alternative theories of gravitation through galactic dynamics. In particular, we modified the Gadget-2 code to probe alternatives theories whose weak field limits have a Yukawa-like gravitational potential. As a first application of this modified Gadget-2 code we simulate the evolution of elliptical galaxies. These simulations show that galactic dynamics can be used to constrain the parameters associated with alternative theories of gravitation.Comment: 6 pages, 5 figures - To appear in General Relativity and Gravitatio

Probing Yukawian gravitational potential by numerical simulations. I. Changing N-body codes

In the weak field limit general relativity reduces, as is well known, to the Newtonian gravitation. Alternative theories of gravity, however, do not necessarily reduce to Newtonian gravitation; some of them, for example, reduce to Yukawa-like potentials instead of the Newtonian potential. Since the Newtonian gravitation is largely used to model with success the structures of the universe, such as for example galaxies and clusters of galaxies, a way to probe and constrain alternative theories, in the weak field limit, is to apply them to model the structures of the universe. In the present study, we consider how to probe Yukawa-like potentials using N-body numerical simulations.Comment: 17 pages, 11 figures. To appear in General Relativity and Gravitatio

Deficiency of Pkc1 activity affects glycerol metabolism in Saccharomyces cerevisiae

In pressProtein kinase C is apparently involved in the control of many cellular systems: the cell wall integrity pathway, the synthesis of ribosomes, the appropriated reallocation of transcription factors under specific stress conditions and also the regulation of N-glycosylation activity. All these observations suggest the existence of additional targets not yet identified. In the context of the control of carbon metabolism, previous data demonstrated that Pkc1 p might play a central role in the control of cellular growth and metabolism in yeast. In particular, it has been suggested that it might be involved in the derepression of genes under glucose-repression by driving an appropriated subcellular localization of transcriptional factors, such as Mig1 p. In this work, we show that pkc1∆ mutant is unable to grow on glycerol because it cannot perform the derepression of GUT1 gene that encodes for glycerol kinase. Additionally, active transport is also partially affected. Using this phenotype, we were able to isolate a new pkc1∆ revertant. We also isolated two transformants identified as the nuclear exportin Msn5 and the histone deacetylase Hos2 extragenic suppressors of this mutation. Based on these results, we postulate that Pkc1 p may be involved in the control of the cellular localization and/or regulation of the activity of nuclear proteins implicated in gene expression.Fundação Universidade Federal de Ouro Preto (FUFOP). Fundação de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) - CBS-1875/95. Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) - 300998/89-9 to R.L.B., 301255/01-6 to L.G.F

Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders

Several clinical trials and experimental studies strongly suggest a place for Saccharomyces boulardii as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanisms of action of S. boulardii and its properties may explain its efficacy and beneficial effects in acute and chronic gastrointestinal diseases that have been confirmed by clinical trials. Caution should be taken in patients with risk factors for adverse events. This review discusses the evidence for efficacy and safety of S. boulardii as a probiotic for the prevention and therapy of gastrointestinal disorders in humans